Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Phase III Adaptive Radiation and Chemotherapy for Muscle Invasive Bladder Cancer Trial (ARCHER)

NCT07097142 is registered in ClinicalTrials.gov with NRG Oncology as lead sponsor.

NCT NCT07097142
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07097142 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Phase III Adaptive Radiation and Chemotherapy for Muscle Invasive Bladder Cancer Trial (ARCHER)
Lead sponsor
NRG Oncology
Phase
Phase 3
Overall status
Recruiting
Start date
October 7, 2025
Completion date
May 31, 2035
Enrollment
486 (estimated)
Sites
211

Conditions

As the registry lists them; a condition with its own page is linked.

muscle invasive bladder urothelial carcinoma, stage ii bladder cancer ajcc v8, stage iiia bladder cancer ajcc v8